#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Diy_coref|
#T_RL=webanno.custom.Diy_coref_re|BT_webanno.custom.Diy_coref


#Text=10.
1-1	0-2	10	_	_	
1-2	2-3	.	_	_	

#Text=Expression of Luciferase In Vivo:
#Text=[0400] 10 .mu.g mRNA coding for luciferase (Luc-RNActive) were mixed in the indicated molar ratio with the respectively peptide (according to formula I), thereby forming a complex.
2-1	4-14	Expression	_	_	
2-2	15-17	of	_	_	
2-3	18-28	Luciferase	_	_	
2-4	29-31	In	_	_	
2-5	32-36	Vivo	_	_	
2-6	36-37	:	_	_	
2-7	38-39	[	_	_	
2-8	39-43	0400	_	_	
2-9	43-44	]	_	_	
2-10	45-47	10	_	_	
2-11	48-49	.	_	_	
2-12	49-53	mu.g	_	_	
2-13	54-58	mRNA	_	_	
2-14	59-65	coding	_	_	
2-15	66-69	for	_	_	
2-16	70-80	luciferase	_	_	
2-17	81-82	(	_	_	
2-18	82-94	Luc-RNActive	_	_	
2-19	94-95	)	_	_	
2-20	96-100	were	_	_	
2-21	101-106	mixed	_	_	
2-22	107-109	in	_	_	
2-23	110-113	the	_	_	
2-24	114-123	indicated	_	_	
2-25	124-129	molar	_	_	
2-26	130-135	ratio	_	_	
2-27	136-140	with	_	_	
2-28	141-144	the	_	_	
2-29	145-157	respectively	_	_	
2-30	158-165	peptide	_	_	
2-31	166-167	(	_	_	
2-32	167-176	according	_	_	
2-33	177-179	to	_	_	
2-34	180-187	formula	_	_	
2-35	188-189	I	_	_	
2-36	189-190	)	_	_	
2-37	190-191	,	_	_	
2-38	192-199	thereby	_	_	
2-39	200-207	forming	_	_	
2-40	208-209	a	_	_	
2-41	210-217	complex	_	_	
2-42	217-218	.	_	_	

#Text=Afterwards the resulting solution was adjusted with Ringer Lactate solution to a final volume of 100 .mu.l und incubated for 30 minutes at room temperature, yielding a solution with a 0.1 g/l concentration of complexed RNA.
#Text=[0401] 100 .mu.l (20 .mu.I) of this solution was administrated intradermally (ear pinna or back) or intramuscularly (m. tibialis) of 7 week old BALB/c mice.
3-1	219-229	Afterwards	*[1]	3-54[2_1]	
3-2	230-233	the	*[1]	_	
3-3	234-243	resulting	*[1]	_	
3-4	244-252	solution	*[1]	_	
3-5	253-256	was	*[1]	_	
3-6	257-265	adjusted	*[1]	_	
3-7	266-270	with	*[1]	_	
3-8	271-277	Ringer	*[1]	_	
3-9	278-285	Lactate	*[1]	_	
3-10	286-294	solution	*[1]	_	
3-11	295-297	to	*[1]	_	
3-12	298-299	a	*[1]	_	
3-13	300-305	final	*[1]	_	
3-14	306-312	volume	*[1]	_	
3-15	313-315	of	*[1]	_	
3-16	316-319	100	*[1]	_	
3-17	320-321	.	*[1]	_	
3-18	321-325	mu.l	*[1]	_	
3-19	326-329	und	*[1]	_	
3-20	330-339	incubated	*[1]	_	
3-21	340-343	for	*[1]	_	
3-22	344-346	30	*[1]	_	
3-23	347-354	minutes	*[1]	_	
3-24	355-357	at	*[1]	_	
3-25	358-362	room	*[1]	_	
3-26	363-374	temperature	*[1]	_	
3-27	374-375	,	*[1]	_	
3-28	376-384	yielding	*[1]	_	
3-29	385-386	a	*[1]	_	
3-30	387-395	solution	*[1]	_	
3-31	396-400	with	*[1]	_	
3-32	401-402	a	*[1]	_	
3-33	403-406	0.1	*[1]	_	
3-34	407-408	g	*[1]	_	
3-35	408-409	/	*[1]	_	
3-36	409-410	l	*[1]	_	
3-37	411-424	concentration	*[1]	_	
3-38	425-427	of	*[1]	_	
3-39	428-437	complexed	*[1]	_	
3-40	438-441	RNA	*[1]	_	
3-41	441-442	.	*[1]	_	
3-42	443-444	[	_	_	
3-43	444-448	0401	_	_	
3-44	448-449	]	_	_	
3-45	450-453	100	_	_	
3-46	454-455	.	_	_	
3-47	455-459	mu.l	_	_	
3-48	460-461	(	_	_	
3-49	461-463	20	_	_	
3-50	464-465	.	_	_	
3-51	465-469	mu.I	_	_	
3-52	469-470	)	_	_	
3-53	471-473	of	_	_	
3-54	474-478	this	*[2]	_	
3-55	479-487	solution	*[2]	_	
3-56	488-491	was	_	_	
3-57	492-505	administrated	_	_	
3-58	506-519	intradermally	_	_	
3-59	520-521	(	_	_	
3-60	521-524	ear	_	_	
3-61	525-530	pinna	_	_	
3-62	531-533	or	_	_	
3-63	534-538	back	_	_	
3-64	538-539	)	_	_	
3-65	540-542	or	_	_	
3-66	543-558	intramuscularly	_	_	
3-67	559-560	(	_	_	
3-68	560-561	m	_	_	
3-69	561-562	.	_	_	
3-70	563-571	tibialis	_	_	
3-71	571-572	)	_	_	
3-72	573-575	of	_	_	
3-73	576-577	7	_	_	
3-74	578-582	week	_	_	
3-75	583-586	old	_	_	
3-76	587-591	BALB	_	_	
3-77	591-592	/	_	_	
3-78	592-593	c	_	_	
3-79	594-598	mice	_	_	
3-80	598-599	.	_	_	

#Text=After 24 h the mice were sacrificed and the samples (ear, skin from the back or muscle) were collected, frozen at -78.degree.
4-1	600-605	After	_	_	
4-2	606-608	24	_	_	
4-3	609-610	h	_	_	
4-4	611-614	the	_	_	
4-5	615-619	mice	_	_	
4-6	620-624	were	_	_	
4-7	625-635	sacrificed	_	_	
4-8	636-639	and	_	_	
4-9	640-643	the	_	_	
4-10	644-651	samples	_	_	
4-11	652-653	(	_	_	
4-12	653-656	ear	_	_	
4-13	656-657	,	_	_	
4-14	658-662	skin	_	_	
4-15	663-667	from	_	_	
4-16	668-671	the	_	_	
4-17	672-676	back	_	_	
4-18	677-679	or	_	_	
4-19	680-686	muscle	_	_	
4-20	686-687	)	_	_	
4-21	688-692	were	_	_	
4-22	693-702	collected	_	_	
4-23	702-703	,	_	_	
4-24	704-710	frozen	_	_	
4-25	711-713	at	_	_	
4-26	714-715	-	_	_	
4-27	715-717	78	_	_	
4-28	717-718	.	_	_	
4-29	718-724	degree	_	_	
4-30	724-725	.	_	_	

#Text=C. and lysed for 3 Minutes at full speed in a tissue lyser (Qiagen, Hilden, Germany).
5-1	726-727	C	_	_	
5-2	727-728	.	_	_	
5-3	729-732	and	_	_	
5-4	733-738	lysed	_	_	
5-5	739-742	for	_	_	
5-6	743-744	3	_	_	
5-7	745-752	Minutes	_	_	
5-8	753-755	at	_	_	
5-9	756-760	full	_	_	
5-10	761-766	speed	_	_	
5-11	767-769	in	_	_	
5-12	770-771	a	_	_	
5-13	772-778	tissue	_	_	
5-14	779-784	lyser	_	_	
5-15	785-786	(	_	_	
5-16	786-792	Qiagen	_	_	
5-17	792-793	,	_	_	
5-18	794-800	Hilden	_	_	
5-19	800-801	,	_	_	
5-20	802-809	Germany	_	_	
5-21	809-810	)	_	_	
5-22	810-811	.	_	_	

#Text=Afterwards 600 .mu.l of lysis buffer were added and the resulting solutions were subjected another 6 minutes at full speed in the tissue lyser.
6-1	812-822	Afterwards	_	_	
6-2	823-826	600	_	_	
6-3	827-828	.	_	_	
6-4	828-832	mu.l	_	_	
6-5	833-835	of	_	_	
6-6	836-841	lysis	_	_	
6-7	842-848	buffer	_	_	
6-8	849-853	were	_	_	
6-9	854-859	added	_	_	
6-10	860-863	and	_	_	
6-11	864-867	the	_	_	
6-12	868-877	resulting	_	_	
6-13	878-887	solutions	_	_	
6-14	888-892	were	_	_	
6-15	893-902	subjected	_	_	
6-16	903-910	another	_	_	
6-17	911-912	6	_	_	
6-18	913-920	minutes	_	_	
6-19	921-923	at	_	_	
6-20	924-928	full	_	_	
6-21	929-934	speed	_	_	
6-22	935-937	in	_	_	
6-23	938-941	the	_	_	
6-24	942-948	tissue	_	_	
6-25	949-954	lyser	_	_	
6-26	954-955	.	_	_	

#Text=After 10 minutes centrifugation at 13500 rpm at 4.degree.
7-1	956-961	After	_	_	
7-2	962-964	10	_	_	
7-3	965-972	minutes	_	_	
7-4	973-987	centrifugation	_	_	
7-5	988-990	at	_	_	
7-6	991-996	13500	_	_	
7-7	997-1000	rpm	_	_	
7-8	1001-1003	at	_	_	
7-9	1004-1005	4	_	_	
7-10	1005-1006	.	_	_	
7-11	1006-1012	degree	_	_	
7-12	1012-1013	.	_	_	

#Text=C. the supernatants were mixed with luciferin buffer (25 mM Glycylglycin, 15 mM MgSO4, 5 mM ATP, 62.5 .mu.M luciferin) and luminiscence was detected using a luminometer (Lumat LB 9507 (Berthold Technologies, Bad Wildbad, Germany)).
#Text=11.
8-1	1014-1015	C	_	_	
8-2	1015-1016	.	_	_	
8-3	1017-1020	the	_	_	
8-4	1021-1033	supernatants	_	_	
8-5	1034-1038	were	_	_	
8-6	1039-1044	mixed	_	_	
8-7	1045-1049	with	_	_	
8-8	1050-1059	luciferin	_	_	
8-9	1060-1066	buffer	_	_	
8-10	1067-1068	(	_	_	
8-11	1068-1070	25	_	_	
8-12	1071-1073	mM	_	_	
8-13	1074-1086	Glycylglycin	_	_	
8-14	1086-1087	,	_	_	
8-15	1088-1090	15	_	_	
8-16	1091-1093	mM	_	_	
8-17	1094-1099	MgSO4	_	_	
8-18	1099-1100	,	_	_	
8-19	1101-1102	5	_	_	
8-20	1103-1105	mM	_	_	
8-21	1106-1109	ATP	_	_	
8-22	1109-1110	,	_	_	
8-23	1111-1115	62.5	_	_	
8-24	1116-1117	.	_	_	
8-25	1117-1121	mu.M	_	_	
8-26	1122-1131	luciferin	_	_	
8-27	1131-1132	)	_	_	
8-28	1133-1136	and	_	_	
8-29	1137-1149	luminiscence	_	_	
8-30	1150-1153	was	_	_	
8-31	1154-1162	detected	_	_	
8-32	1163-1168	using	_	_	
8-33	1169-1170	a	_	_	
8-34	1171-1182	luminometer	_	_	
8-35	1183-1184	(	_	_	
8-36	1184-1189	Lumat	_	_	
8-37	1190-1192	LB	_	_	
8-38	1193-1197	9507	_	_	
8-39	1198-1199	(	_	_	
8-40	1199-1207	Berthold	_	_	
8-41	1208-1220	Technologies	_	_	
8-42	1220-1221	,	_	_	
8-43	1222-1225	Bad	_	_	
8-44	1226-1233	Wildbad	_	_	
8-45	1233-1234	,	_	_	
8-46	1235-1242	Germany	_	_	
8-47	1242-1243	)	_	_	
8-48	1243-1244	)	_	_	
8-49	1244-1245	.	_	_	
8-50	1246-1248	11	_	_	
8-51	1248-1249	.	_	_	

#Text=Detection of Antigen-Specific Antibodies:
#Text=[0402] C57 BL/6 mice were vaccinated 2 times on day 1 and day 15 with 20 .mu.g formulated RNActive-derived mRNA coding for Gallus gallus Ovalbumine in 100 .mu.l RiLa solution. 1 week after the last vaccination blood samples were collected and expression of Ovalbumine-specific antibodies was determined.
9-1	1250-1259	Detection	_	_	
9-2	1260-1262	of	_	_	
9-3	1263-1279	Antigen-Specific	_	_	
9-4	1280-1290	Antibodies	_	_	
9-5	1290-1291	:	_	_	
9-6	1292-1293	[	_	_	
9-7	1293-1297	0402	_	_	
9-8	1297-1298	]	_	_	
9-9	1299-1302	C57	_	_	
9-10	1303-1305	BL	_	_	
9-11	1305-1306	/	_	_	
9-12	1306-1307	6	_	_	
9-13	1308-1312	mice	_	_	
9-14	1313-1317	were	_	_	
9-15	1318-1328	vaccinated	_	_	
9-16	1329-1330	2	_	_	
9-17	1331-1336	times	_	_	
9-18	1337-1339	on	_	_	
9-19	1340-1343	day	_	_	
9-20	1344-1345	1	_	_	
9-21	1346-1349	and	_	_	
9-22	1350-1353	day	_	_	
9-23	1354-1356	15	_	_	
9-24	1357-1361	with	_	_	
9-25	1362-1364	20	_	_	
9-26	1365-1366	.	_	_	
9-27	1366-1370	mu.g	_	_	
9-28	1371-1381	formulated	_	_	
9-29	1382-1398	RNActive-derived	_	_	
9-30	1399-1403	mRNA	_	_	
9-31	1404-1410	coding	_	_	
9-32	1411-1414	for	_	_	
9-33	1415-1421	Gallus	_	_	
9-34	1422-1428	gallus	_	_	
9-35	1429-1439	Ovalbumine	_	_	
9-36	1440-1442	in	_	_	
9-37	1443-1446	100	_	_	
9-38	1447-1448	.	_	_	
9-39	1448-1452	mu.l	_	_	
9-40	1453-1457	RiLa	_	_	
9-41	1458-1466	solution	_	_	
9-42	1466-1467	.	_	_	
9-43	1468-1469	1	_	_	
9-44	1470-1474	week	_	_	
9-45	1475-1480	after	_	_	
9-46	1481-1484	the	_	_	
9-47	1485-1489	last	_	_	
9-48	1490-1501	vaccination	_	_	
9-49	1502-1507	blood	_	_	
9-50	1508-1515	samples	_	_	
9-51	1516-1520	were	_	_	
9-52	1521-1530	collected	_	_	
9-53	1531-1534	and	_	_	
9-54	1535-1545	expression	_	_	
9-55	1546-1548	of	_	_	
9-56	1549-1568	Ovalbumine-specific	_	_	
9-57	1569-1579	antibodies	_	_	
9-58	1580-1583	was	_	_	
9-59	1584-1594	determined	_	_	
9-60	1594-1595	.	_	_	
